Baird analyst Madhu Kumar reiterated an Overweight rating on The Medicines Co and raised his price target to $110 from $80. On Saturday, the company announced Phase 2 open-label extension ORION-3 data for PCSK9 RNAi drug inclisiran for hypercholesterolemia at the National Lipid Association meeting, Kumar tells investors in a research note, adding that these results have increased his conviction in inclisiran "ascending the Iron Throne" of PCSK9 drugs in ORION-9/10/11, for which top-line data are guided for in the third quarter. Phase 2 OLE results, he says, have effectively quashed bear safety concerns for inclisiran.